



Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 28 April 2023

Ref No: TCPCL/SEC/2023-24/00007

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

Scrip Code: 543321

Subject: Fund raising by issuance of debt securities by Large Corporates

Ref.: Chapter XII of Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated on April 13, 2022

Dear Sir/Madam,

Pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated on April 13, 2022, we hereby confirm that Tatva Chintan Pharma Chem Limited is not a Large Corporate as per the applicability criteria mentioned in clause 1.2 of Chapter XII of the above mentioned SEBI circular.

The details required as per the above circular are enclosed as Annexure - XII – B2

We request you to kindly take the same on record.

Thanking You,

Your Faithfully,
For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444

Enclosed: As above

Annexure - XII – B2

Format of the annual disclosure to be made by an entity identified as a LC*
(to be submitted to the stock exchange(s) within 45 days of the end of the FY)

1. Name of the Company: **TATVA CHINTAN PHARMA CHEM LIMITED**
2. CIN: **L24232GJ1996PLC029894**
3. Report filed for FY: 2022-23 (T)
4. Details of the current block (all figures in Rs. crore):

Sr. No.	Particulars	Details
1.	2-year block period (specify financial years)	FY 2022-23 and FY 2023-24
2.	Incremental borrowing done in FY (T) (a)	N.A.
3.	Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)	N.A.
4.	Actual borrowing done through debt securities in FY (T) (c)	N.A.
5.	Shortfall in the borrowing through debt securities, if any, for FY (T-1) carried forward to FY (T). (d)	N.A.
6.	Quantum of (d), which has been met from (c) (e)	N.A.
7.	Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) {after adjusting for any shortfall in borrowing for FY (T-1) which was carried forward to FY (T)} (f) = (b) - [(c) - (e)] {If the calculated value is zero or negative, write "nil"}	N.A.

5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs. crore):

Sr. No.	Particulars	Details
1.	2-year block period (specify financial years)	FY 2021-22 and FY 2022-23
2.	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)}#	N.A.

We confirm that **we are not a Large Corporate** as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021, as amended.

For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary
Membership No.: **A37444**
Tel: +91 75748 48533
E-mail: cs@tatvachintan.com

Ashok Bothra
Chief Financial Officer
Tel: +91 75748 48533
E-mail: finance@tatvachintan.com

Date – 28/04/2023